Idursulfase - Green Cross

Drug Profile

Idursulfase - Green Cross

Alternative Names: GC 1123; GC-1111; GC1111B; Hunterase; Iduronate-2-sulfatase - Green Cross; Idursulfase beta; Recombinant human iduronate-2-sulfatase - Green Cross; Recombinant human iduronate-w-sulfatase

Latest Information Update: 07 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Green Cross
  • Class Iduronate sulfatases
  • Mechanism of Action Iduronate sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis II
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Mucopolysaccharidosis II

Most Recent Events

  • 25 Oct 2016 Phase-I/II clinical trials in Mucopolysaccharidosis II in Japan (Intracerebral)
  • 03 Feb 2016 Green Cross Corporation plans a phase II trial for Mucopolysaccharidosis-II in USA (NCT02663024)
  • 01 Sep 2013 Green Cross completes phase III trial for Mucopolysaccharidosis II (in children) in South Korea (NCT01645189)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top